Research ArticleOriginal Article

Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multi-institutional analysis (KROG 19-04)

Sung Uk Lee, Jinsil Seong, Tae Hyun Kim, Jung Ho Im, Woo Chul Kim, Kyubo Kim, Hae Jin Park, Tae Gyu Kim, Youngkyong Kim, Bae Kwon Jeong, Jin Hee Kim, Byoung Hyuck Kim and Taek-Keun Nam
Cancer Biology & Medicine June 2022, 19 (6) 931-944; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0667

References

  1. 1.↵
    2. Sharma A,
    3. Sharma KL,
    4. Gupta A,
    5. Yadav A,
    6. Kumar A.
    Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol. 2017; 23: 3978–98.
    OpenUrlPubMed
  2. 2.↵
    2. Jarnagin WR,
    3. Ruo L,
    4. Little SA,
    5. Klimstra D,
    6. D’Angelica M,
    7. DeMatteo RP, et al.
    Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003; 98: 1689–700.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    2. Wang J,
    3. Narang AK,
    4. Sugar EA,
    5. Luber B,
    6. Rosati LM,
    7. Hsu CC, et al.
    Evaluation of adjuvant radiation therapy for resected gallbladder carcinoma: a multi-institutional experience. Ann Surg Oncol. 2015; 22: S1100–6.
    OpenUrl
  4. 4.
    2. Czito BG,
    3. Hurwitz HI,
    4. Clough RW,
    5. Tyler DS,
    6. Morse MA,
    7. Clary BM, et al.
    Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys. 2005; 62: 1030–4.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. Kresl JJ,
    3. Schild SE,
    4. Henning GT,
    5. Gunderson LL,
    6. Donohue J,
    7. Pitot H, et al.
    Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys. 2002; 52: 167–75.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Takada T,
    3. Amano H,
    4. Yasuda H,
    5. Nimura Y,
    6. Matsushiro T,
    7. Kato H, et al.
    Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002; 95: 1685–95.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    2. Park JS,
    3. Yoon DS,
    4. Kim KS,
    5. Choi JS,
    6. Lee WJ,
    7. Chi HS, et al.
    Actual recurrence patterns and risk factors influencing recurrence after curative resection with stage II gallbladder carcinoma. J Gastrointest Surg. 2007; 11: 631–7.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    2. Kim WS,
    3. Choi DW,
    4. You DD,
    5. Ho CY,
    6. Heo JS,
    7. Choi SH.
    Risk factors influencing recurrence, patterns of recurrence, and the efficacy of adjuvant therapy after radical resection for gallbladder carcinoma. J Gastrointest Surg. 2010; 14: 679–87.
    OpenUrlPubMed
  9. 9.↵
    2. Cho SY,
    3. Kim SH,
    4. Park SJ,
    5. Han SS,
    6. Kim YK,
    7. Lee KW, et al.
    Adjuvant chemoradiation therapy in gallbladder cancer. J Surg Oncol. 2010; 102: 87–93.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.
    2. Duffy A,
    3. Capanu M,
    4. Abou-Alfa GK,
    5. Huitzil D,
    6. Jarnagin W,
    7. Fong Y, et al.
    Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol. 2008; 98: 485–9.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.
    2. Hyder O,
    3. Dodson RM,
    4. Sachs T,
    5. Weiss M,
    6. Mayo SC,
    7. Choti MA, et al.
    Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: a propensity score-matched surveillance, epidemiology, and end results analysis. Surgery. 2014; 155: 85–93.
    OpenUrl
  12. 12.↵
    2. Kim TH,
    3. Woo SM,
    4. Lee WJ,
    5. Oh ES,
    6. Youn SH,
    7. Moon SH, et al.
    Benefit of adjuvant chemoradiotherapy in resected gallbladder carcinoma. Sci Rep. 2019; 9: 11770.
  13. 13.↵
    2. Lee HC,
    3. Lee JH,
    4. Lee SW,
    5. Lee JH,
    6. Yu M,
    7. Jang HS, et al.
    Retrospective analysis of intensity-modulated radiotherapy and three-dimensional conformal radiotherapy of postoperative treatment for biliary tract cancer. Radiat Oncol J. 2019; 37: 279–85.
    OpenUrl
  14. 14.↵
    2. Ben-Josef E,
    3. Guthrie KA,
    4. El-Khoueiry AB,
    5. Corless CL,
    6. Zalupski MM,
    7. Lowy AM, et al.
    SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015; 33: 2617–22.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    2. Kim Y,
    3. Amini N,
    4. Wilson A,
    5. Margonis GA,
    6. Ethun CG,
    7. Poultsides G, et al.
    Impact of chemotherapy and external-beam radiation therapy on outcomes among patients with resected gallbladder cancer: a multi-institutional analysis. Ann Surg Oncol. 2016; 23: 2998–3008.
    OpenUrlCrossRefPubMed
  16. 16.
    2. Im JH,
    3. Lee WJ,
    4. Kang CM,
    5. Hwang HK,
    6. Seong J.
    Prognostic factors and patterns of loco-regional failure in patients with R0 resected gallbladder cancer. HPB (Oxford). 2020; 22: 1168–73.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Kim TG.
    Patterns of initial failure after resection for gallbladder cancer: implications for adjuvant radiotherapy. Radiat Oncol J. 2017; 35: 359–67.
    OpenUrlCrossRefPubMed
  18. 18.↵
    2. Wang SJ,
    3. Lemieux A,
    4. Kalpathy-Cramer J,
    5. Ord CB,
    6. Walker GV,
    7. Fuller CD, et al.
    Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol. 2011; 29: 4627–32.
    OpenUrlAbstract/FREE Full Text
  19. 19.
    2. Manterola C,
    3. Duque G,
    4. Grande L,
    5. de Aretxabala X,
    6. Conejeros R,
    7. Otzen T, et al.
    A systematic review of the effectiveness of adjuvant therapy for patients with gallbladder cancer. HPB (Oxford). 2019; 21: 1427–35.
    OpenUrl
  20. 20.↵
    2. Mantripragada KC,
    3. Hamid F,
    4. Shafqat H,
    5. Olszewski AJ.
    Adjuvant therapy for resected gallbladder cancer: analysis of the national cancer data base. J Natl Cancer Inst. 2017; 109: djw202.
  21. 21.↵
    2. Mitin T,
    3. Enestvedt CK,
    4. Jemal A,
    5. Sineshaw HM.
    Limited use of adjuvant therapy in patients with resected gallbladder cancer despite a strong association with survival. J Natl Cancer Inst. 2017; 109: djw324.
  22. 22.↵
    2. Kim BH,
    3. Kwon J,
    4. Chie EK,
    5. Kim K,
    6. Kim YH,
    7. Seo DW, et al.
    Adjuvant chemoradiotherapy is associated with improved survival for patients with resected gallbladder carcinoma: a systematic review and meta-analysis. Ann Surg Oncol. 2018; 25: 255–64.
    OpenUrlCrossRefPubMed
  23. 23.↵
    2. Jensen EH,
    3. Abraham A,
    4. Jarosek S,
    5. Habermann EB,
    6. Al-Refaie WB,
    7. Vickers SA, et al.
    Lymph node evaluation is associated with improved survival after surgery for early stage gallbladder cancer. Surgery. 2009; 146: 706–13.
    OpenUrlCrossRefPubMed
  24. 24.↵
    2. Horgan AM,
    3. Amir E,
    4. Walter T,
    5. Knox JJ.
    Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012; 30: 1934–40.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    2. Primrose JN,
    3. Fox RP,
    4. Palmer DH,
    5. Malik HZ,
    6. Prasad R,
    7. Mirza D, et al.
    Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019; 20: 663–73.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords